Bloomberg did not build a terminal. It built an epistemology—a shared framework for how financial professionals interpret price signals, execute trades, and construct narratives about market conditions. The data was always secondary to the interpretive infrastructure around it. When Jay Joshi of Daily Remedy describes MedPricer as a potential ‘Bloomberg-style terminal for drug pricing signals,’ the analogy is precise in one sense and deeply ambitious in another. The data exists. The interpretive infrastructure—the shared professional language, the normalized workflow, the real-time signal extraction—does not yet.
What Bloomberg Actually Built
Bloomberg’s competitive advantage was not proprietary data. Much of what it delivered—bond prices, earnings reports, economic releases—was available from other sources. What Bloomberg built was the fastest, most normalized, most analytically integrated presentation of that data, combined with a communication layer (the Bloomberg message system) that embedded it in professional workflows. By the time a financial professional could access an alternative, Bloomberg had become the medium through which they thought about markets.
The pharmaceutical pricing analogue would require: real-time or near-real-time WAC change alerts, ASP trend projections based on historical spread dynamics, NADAC volatility signals with supply-event attribution, and an alert system that flags statistically significant divergences between benchmarks before they appear in public filings. That is a meaningfully different product from a dashboard that displays normalized pricing data.
The Professional Workflow Problem
A Bloomberg terminal succeeds partly because financial professionals spend their workdays inside it. The terminal is the environment in which analysis occurs, not a resource consulted for specific lookups. Building a pharmaceutical pricing product with similar stickiness would require pharmaceutical pricing analysis to become a daily workflow activity—which it is, for hospital formulary committees, for PBM contracting teams, for hedge fund analysts covering pharma. The question is whether those workflows currently occur inside any single platform or are distributed across spreadsheets, vendor databases, and manual data pulls.
MedPricer’s opportunity is in that distribution. If pharmaceutical pricing analysis is currently occurring in a fragmented, manual, multi-source environment, a normalized, integrated platform can capture workflow hours that are currently being spent on data preparation rather than analysis. That is the same problem Bloomberg solved in fixed income markets in the 1980s.
The Licensing Model and Its Implications
Bloomberg’s $25,000-per-seat annual license is sustainable because the terminal is a professional prerequisite—not a luxury but an infrastructure cost. Pharmaceutical pricing data of the quality and normalization MedPricer is building would command institutional pricing if—and only if—it becomes embedded in professional workflows the way Bloomberg became embedded in trading desks.
The path to that embedding requires specific actions: direct API integration into the research platforms used by healthcare equity analysts, data licensing arrangements with institutional research providers, and potentially a co-branded data product with a healthcare information company with existing professional relationships. The dashboard alone will not create the dependency. The workflow integration will.
What the Analogy Leaves Out
Bloomberg operates in a market with relatively transparent underlying transactions. Bond prices are public. Equity trades are reported. Economic data is released on schedule. The pharmaceutical pricing market has no equivalent transparency. Rebate contracts are confidential. Net manufacturer revenue is disclosed only in aggregate. The ASP lag means that even the most current public data is months old.
A drug pricing terminal operating on public data alone will always be making inferences from incomplete information. That is not a disqualifying limitation—Bloomberg’s early fixed income data was also incomplete, and the terminal was useful precisely because it made the best available inference in the fastest possible way. But it is a structural feature of the market that MedPricer’s investors and design team need to incorporate into the product concept: the terminal will deal in probabilities and signals, not transactions. That is a different product for a different kind of professional workflow.
